Kamada stock gained 1.34 percent as KedRAB demand rose

Published on 10/05/2026 at 09:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kamada stock delivered USD 100 million in first-half 2026 revenue, while adjusted EBITDA reached USD 26 million. The company also confirmed KedRAB capacity for rising U.S. demand.

KMDA, IL0010941198, Illustration mit AI erstellt.

Kamada Ltd. (ISIN IL0010941198) was last at USD 8.31 on Nasdaq on October 2, 2026, up 1.34 percent from the previous session. The company had confirmed on September 17 that KedRAB inventory and manufacturing capacity could support higher U.S. demand after a nationwide rise in rabies exposures.

KedRAB demand meets available supply

According to Kamada on September 17, 2026, KedRAB is one of two FDA-approved anti-rabies immunoglobulin products in the United States. The company estimates the U.S. rabies immunoglobulin market at USD 200 million annually and supplies KedRAB through Kedrion Biopharma.

The supply statement matters because Kamada identified higher rabies exposure and post-exposure prophylaxis use as a demand driver. It also highlighted a vertically integrated supply chain and an in-house rabies testing laboratory as operating advantages.

First-half growth supports guidance

At a September 24 investor conference, Investing.com reported first-half 2026 revenue of USD 100 million and adjusted EBITDA of USD 26 million. Adjusted EBITDA represented a 26 percent margin and grew 14 percent from the first half of 2025, while revenue increased 13 percent.

The same conference summary said Kamada maintained 2026 revenue guidance of USD 200 million to USD 205 million and adjusted EBITDA guidance of USD 50 million to USD 53 million. First-half revenue therefore stood at the midpoint of the full-year revenue range, giving investors a quantified checkpoint against management's unchanged plan.

MarketBeat reported a Buy consensus from four analysts and an average price target of USD 13.50. That target lies 62.5 percent above the USD 8.31 Nasdaq price, while the same report said Kamada's latest quarterly EPS was USD 0.16 against a USD 0.11 consensus.

Stock remains below yearly high

KMDA's October 2 reference price was USD 1.04 below its 52-week high of USD 9.35 and USD 1.81 above its 52-week low of USD 6.50. Trading volume was 57,878 shares, and market capitalization stood at USD 479.4 million on the same date.

The next checkpoint is November 16, 2026, which Investing.com lists for Kamada's next results. The combination of demand-sensitive KedRAB sales, first-half profitability and unchanged guidance leaves the upcoming report as the clearest test of whether the company can sustain its 2026 trajectory.

USD 8.31 price and USD 479.4 million value

Kamada stock was last at USD 8.31 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a 52-week range of USD 6.50 to USD 9.35 and market capitalization of USD 479.4 million.